RT @manjuggm@twitter.com

It would be great for #MRD testing companies to develop a patient perspective questionnaire to use with the tests that patients could opt in or out into.
"With great tests come great responsibilities"
@NateraOncology@twitter.com @GuardantHealth@twitter.com @HaystackMRD@twitter.com https://twitter.com/guildsman/status/1615888479036268547

🐦🔗: https://twitter.com/manjuggm/status/1615892831800803329

RT @OncoJurdi@twitter.com

GALAXY arm from CIRCULATE-JAPAN just published in @NatureMedicine@twitter.com reporting #ctDNA #MRD and efficacy of adjuvant chemotherapy in patients with colorectal cancer with 18 month DFS. https://rdcu.be/c3zoC
a🧵

🐦🔗: https://twitter.com/OncoJurdi/status/1615400556675096576

RT @sanamloghavi@twitter.com

Looking forward to reading this in detail.Big #hemepath #leusm and #MRD implications Congrats to the authors. Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia ⁦⁦@BloodAdvances@twitter.com⁩ https://ashpublications.org/bloodadvances/article/7/1/167/486809/Integrated-flow-cytometry-and-sequencing-to

🐦🔗: https://twitter.com/sanamloghavi/status/1612937159874420736

First insights on #ctDNA extended #genomic characterization in early #BreastCancer without the support of primary #tumor #NGS. Multiparametric features (e.g CNVs) are crucial for refining minimal residual disease #MRD detection and profiling #PrecisionMedicine #LiquidBiopsy #bcsm

First insights on #ctDNA extended #genomic characterization in early #BreastCancer without the support of primary #tumor #NGS. Multiparametric features (e.g CNVs) are crucial for refining minimal residual disease #MRD detection and profiling #PrecisionMedicine #LiquidBiopsy #bcsm https://t.co/dyiV3eDo3F